Power Wheelchair Group 3 denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for power wheelchair group3 are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana May Deny a Group 3 Power Wheelchair as Not FDA-Approved — and Why That Is Almost Always Wrong

A "not FDA-approved" denial applied to a Group 3 complex rehab power wheelchair is relatively rare and, when it occurs, often reflects a documentation or coding error rather than a genuine regulatory determination. Power wheelchairs are regulated by the FDA as Class II medical devices and must receive clearance (typically via the 510(k) pathway) before they can be marketed in the United States. A denial claiming the requested device lacks FDA approval should trigger immediate verification of whether the denial is based on accurate information about the specific device.

## Why This Denial Is Appealable

If the device has FDA clearance — which virtually all commercially available Group 3 power wheelchairs do — the stated basis for denial is factually incorrect, and the appeal can lead with that correction. If the denial was triggered by a device coding issue (wrong HCPCS code, ambiguous model description, or a newer feature not yet mapped in Humana's fee schedule), correcting the documentation may resolve the issue without a formal appeal. Either way, this type of denial should not stand unchallenged.

## Federal Appeal Framework

• Internal appeal: File promptly within the EOB deadline. Present the device's FDA clearance documentation as the primary exhibit. Standard pre-service review: 30 days; expedited: 72 hours.
• External review (ACA §2719): If Humana upholds the denial, file for external review within approximately four months. An external reviewer applying generally accepted clinical and regulatory standards is unlikely to uphold a denial of an FDA-cleared device on "not FDA-approved" grounds when clearance is documented.
• ERISA §503: Request the complete claim file. Confirm what specific regulatory basis Humana cited and what documentation — if any — supports that determination.

## Documentation to Gather

• FDA clearance letter: Obtain from the device manufacturer the 510(k) clearance letter or the FDA device registration documentation for the specific model requested. This is your primary rebuttal document.
• HCPCS coding confirmation: Work with the prescribing clinician and the DME supplier to confirm that the device was submitted under the correct HCPCS code and that the code mapping is consistent with Humana's coverage policy.
• Medical necessity documentation: Even if the regulatory objection is resolved, ensure the clinical record independently supports medical necessity — denials can shift rationale between levels of appeal.
• Manufacturer support letter: Major complex rehab technology manufacturers have reimbursement support teams that can provide clearance documentation and assist in challenging coverage denials based on regulatory misclassification.

## Criteria-Mapping Structure

Lead the appeal letter with a direct, factual correction: cite the device name and model, the FDA clearance number, and the clearance date. Then move to the medical necessity documentation as a secondary argument. Keep the two arguments structurally separate so the reviewer can address each independently — and so a victory on the regulatory argument cannot be ignored by pivoting to a new medical necessity objection.